Dr Gordon Duncan
Honorary Clinical Senior Lecturer, Consultant Physician & NHS Research Scotland Career Research Fellow
- Centre for Clinical Brain Sciences, Division of Psychiatry
- Anne Rowling Regenerative Neurology Clinic
- NHS Lothian
Contact details
- Tel: 0131 465 9002
- Email: gordon.duncan@ed.ac.uk
Background
2017 - present: NHS Research Scotland Career Research Fellow
2014 - present: Consultant Physician, NHS Lothian
2011 – 2014: Clinical Research Fellow, Institute for Ageing and Health, Newcastle University
2007 – 2014: Higher Specialist Training in Geriatric Medicine and General Internal Medicine, Northern Deanery
Qualifications
2017: FRCP (Edinburgh)
2014: PhD – Newcastle University
2002: MBChB – University of Dundee
2000: BMSc (Hons) – University of Dundee
Research summary
Parkinson’s disease (PD) is a progressive and disabling neurodegenerative disorder which encompasses abnormal movements, neuropsychiatric disturbances, autonomic dysfunction and ultimately, dementia. There are approximately 10,000 people living with PD in Scotland. In common with other neurodegenerative disorders, treatment remains symptomatic and there are no disease-modifying therapies commercially available.
I am committed to involving people with Parkinson’s in research. My experience of performing laboratory research, observational studies and clinical trials has shown me that a collaborative translational approach is essential and that partnerships between NHS clinicians, academics and industry are an effective way of delivering high quality clinical research.
Research aims and interests
We are building a translational clinical research programme for Parkinson’s disease and associated neurodegenerative disorders which will, for the first time, unite the established experimental research programmes of Edinburgh University with clinical medicine.
People with Parkinson’s will be given the opportunity to participate in CTIMPs of novel treatments for all stages of PD and also for the non-motor features such as dementia, psychosis, sleep disorders and autonomic dysfunction. Our ultimate aim is to conduct CTIMPs for potentially disease-modifying and regenerative therapies.